TY - JOUR
T1 - ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells
AU - Hojo, Takayuki
AU - Maishi, Nako
AU - Towfik, Alam Mohammad
AU - Akiyama, Kosuke
AU - Ohga, Noritaka
AU - Shindoh, Masanobu
AU - Hida, Yasuhiro
AU - Minowa, Kazuyuki
AU - Fujisawa, Toshiaki
AU - Hida, Kyoko
N1 - Publisher Copyright:
© Hojo et al.
PY - 2017
Y1 - 2017
N2 - Reactive oxygen species (ROS) are unstable molecules that activate oxidative stress. Because of the insufficient blood flow in tumors, the tumor microenvironment is often exposed to hypoxic condition and nutrient deprivation, which induces ROS accumulation. We isolated tumor endothelial cells (TECs) and found that they have various abnormalities, although the underlying mechanisms are not fully understood. Here we showed that ROS were accumulated in tumor blood vessels and ROS enhanced TEC migration with upregulation of several angiogenesis related gene expressions. It was also demonstrated that these genes were upregulated by regulation of Nuclear factor erythroid 2-related factor 2 (NRF2). Among these genes, we focused on Biglycan, a small leucine-rich proteoglycan. Inhibition of Toll-like receptors 2 and 4, known BIGLYCAN (BGN) receptors, cancelled the TEC motility stimulated by ROS. ROS inhibited NRF2 expression in TECs but not in NECs, and NRF2 inhibited phosphorylation of SMAD2/3, which activates transcription of BGN. These results indicated that ROS-induced BGN caused the pro-angiogenic phenotype in TECs via NRF2 dysregulation.
AB - Reactive oxygen species (ROS) are unstable molecules that activate oxidative stress. Because of the insufficient blood flow in tumors, the tumor microenvironment is often exposed to hypoxic condition and nutrient deprivation, which induces ROS accumulation. We isolated tumor endothelial cells (TECs) and found that they have various abnormalities, although the underlying mechanisms are not fully understood. Here we showed that ROS were accumulated in tumor blood vessels and ROS enhanced TEC migration with upregulation of several angiogenesis related gene expressions. It was also demonstrated that these genes were upregulated by regulation of Nuclear factor erythroid 2-related factor 2 (NRF2). Among these genes, we focused on Biglycan, a small leucine-rich proteoglycan. Inhibition of Toll-like receptors 2 and 4, known BIGLYCAN (BGN) receptors, cancelled the TEC motility stimulated by ROS. ROS inhibited NRF2 expression in TECs but not in NECs, and NRF2 inhibited phosphorylation of SMAD2/3, which activates transcription of BGN. These results indicated that ROS-induced BGN caused the pro-angiogenic phenotype in TECs via NRF2 dysregulation.
UR - http://www.scopus.com/inward/record.url?scp=85022204560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85022204560&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.17567
DO - 10.18632/oncotarget.17567
M3 - Article
C2 - 28525375
AN - SCOPUS:85022204560
SN - 1949-2553
VL - 8
SP - 45484
EP - 45495
JO - Oncotarget
JF - Oncotarget
IS - 28
ER -